The peritoneal membrane in chronic peritoneal dialysis

Kidney International

Volumn 55, Issue 1, 1999, Pages 341-356

  Krediet, Raymond T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Aquaporin; CA 125; Mesothelial cell markers; Peritoneal sclerosis; Peritoneal transport

Indexed keywords

CIPROFLOXACIN;

ADULT; BACTERIAL PERITONITIS; BACTERIUM IDENTIFICATION; CASE REPORT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GALLSTONE; HEMODIALYSIS; HUMAN; INTESTINE OBSTRUCTION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MALE; PANCREATITIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RECURRENT INFECTION; SHORT SURVEY; STAPHYLOCOCCUS EPIDERMIDIS; TOTAL PARENTERAL NUTRITION;

EID: 0032930760     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00264.x     Document Type: Article

References (152)

1. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore H, Nielsen MP: Peritoneal equilibration test. Perit Dial Bull 7:138-147, 1987
2. Krediet RT, Pannekeet MM, Zemel D, Koomen GCM, Struijk DG, Hoek FJ: Markers of peritoneal membrane status. Perit Dial Bull 16(Suppl 1):S42-S49, 1996
3. Ho-Dac-Pannekeet MM, Krediet RT: Inflammatory changes in vivo during CAPD: What can the effluent tell us? Kidney Int 50(Suppl 56):S12-S16, 1996
4. Rasio EA: Metabolic control of permeability in isolated mesentery. Am J Physiol 226:962-968, 1974
5. Flessner MF: Osmotic barrier of the parietal peritoneum. Am J Physiol 267:F861-F870, 1994
6. Crone C, Levitt DG: Capillary permeability to small solutes, in Handbook of Physiology (vol 4), edited by Renkin EM, Michel CC, Washington DC, American Physiological Society, 1984, pp 411-465
7. Rippe B, Haraldsson B: Transport of macromolecules across microvascular walls: The two pore theory. Physiol Rev 74:163-219, 1994
8. Zemel D, Krediet RT, Koomen GCM, Struijk DG, Arisz L: Day to day variability of protein transport used as a method for analyzing peritoneal permeability in CAPD. Perit Dial Int 11:217-223, 1991
9. Imholz ALT, Koomen GCM, Struijk DG, Arisz L, Krediet RT: Effect of dialysate osmolarity on the transport of low-molecular-weight solutes and proteins during CAPD. Kidney Int 43:1339-1346, 1993
10. Krediet RT, Boeschoten EW, Zuyderhoudt FMJ, Arisz L: The relationship between peritoneal glucose absorption and body fluid loss by ultrafiltration during continuous ambulatory peritoneal dialysis. Clin Nephrol 17:43-52, 1987
11. Rippe B, Stelin G, Haraldson B: Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 40:315-325, 1991
12. Pannekeet MM, Mulder JB, Weening JJ, Struijk DG, Zweers MM, Krediet RT: Demonstration of aquaporin-CHIP in peritoneal tissue of uremic and CAPD patients. Perit Dial Int 6 (Suppl 1):S54-S57, 1996
13. Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B: Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 38:495-506, 1990
14. Ho-Dac-Pannekeet MM, Krediet RT: Water channels in the peritoneum. Perit Dial Int 16:255-259, 1996
15. Rippe B, Stelin G: Simulations of peritoneal solute transport during CAPD: Application of two-pore formalism. Kidney Int 35:1234-1244, 1989
16. Ho-Dac-Pannekeet MM, Schouten N, Langedijk MJ, Hiralall JK, De Waart DR, Struijk DG, Krediet RT: Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 50:979-986, 1996
17. Grahame GR, Torchia MG, Dankewich KA, Ferguson IA: Surface active material in peritoneal effluent of CAPD patients. Perit Dial Bull 5:109-111, 1985
18. Di Paolo N, Buoncristiani U, Capotondo L, Gaggiotti E, De Mia M, Rossi P, Sansoni E, Berninini M: Phosphatidylcholine and peritoneal transport during peritoneal dialysis. Nephron 44:365-370, 1986
19. Williams JD, Beavis JM: Phosphatidylcholine and peritoneal dialysis. Contrib Nephrol 85:142-149, 1990
20. Beavis J, Harwood JL, Coles GA, Williams JD: Synthesis of phospholipids by human peritoneal mesothelial cells. Perit Dial Int 14:348-355, 1994
21. Yung S, Coles GA, Williams JD, Davies M: The source and possible significance of hyaluronan in the peritoneal cavity. Kidney Int 46:527-533, 1994
22. Roboz J, Greaves J, Silides D, Chahinian AP, Holland JF: Hyaluronic acid content of effusion as a diagnostic aid for malignant mesothelioma. Cancer Res 45:1850-1854, 1985
23. Yung S, Thomas GJ, Stylianou E, Williams JD, Coles GA, Davies M: Source of peritoneal proteoglycans: Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans. Am J Pathol 146:520-529, 1995
24. Nagata Y, Matsumura F, Motoyoski H, Yamasaki H, Fukuda K, Tanaka S: Secretion of hyaluronic acid from synovial fibroblasts is enhanced by histamine. J Lab Clin Med 120:707-712, 1992
25. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887, 1983
26. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB: Tissue distribution of a coelomic-epithelial-related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol 2:275-285, 1983
27. Koomen GCM, Betjes MGH, Zemel D, Krediet RT, Hoek FJ: Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Perit Dial Int 14:132-136, 1994
28. Visser CE, Brouwer-Steenbergen JJE, Betjes MGH, Koomen GCM, Beelen RHJ, Krediet RT: Cancer antigen 125: A bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 10:64-69, 1995
29. Pannekeet MM, Zemel D, Koomen GCM, Struijk DG, Krediet RT: Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Perit Dial Int 15:217-225, 1995
30. Ho-Dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT: Longitudinal follow-up of CA 125 in peritoneal effluent. Kidney Int 51:888-893, 1997
31. Pannekeet MM, Koomen GCM, Struijk DG, Krediet RT: Dialysate CA 125 in stable CAPD patients: No relation with transport parameters. Clin Nephrol 44:248-254, 1995
32. Fessler JH, Fessler LI: Biosynthesis of procollagen. Annu Rev Biochem 47:129-162, 1978
33. Rohde H, Vargas L, Hahn E, Kalbfleisch H, Bruguera M, Timpl R: Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 9:451-459, 1979
34. Low RB, Cutroneo KR, Davis GS, Giancola MS: Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest 48:755-759, 1983
35. Joffe P, Jensen LT: Type I and III procollagens in CAPD: Markers of peritoneal fibrosis. Adv Perit Dial 7:158-160, 1991
36. Digenis GE, Dombros NV, Christophoraki M, Grapsa I, Savidis N, Patseris J, Samuilidou E, Zerefos N, Tourkantonis A: Procollagen type-I in serum and dialysate of continuous ambulatory peritoneal dialysis patients. Perit Dial Int 13(Suppl 2):S480-S483, 1993
37. Dobbie JW: Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 12:14-27, 1992
38. Gotloib L, Bar-Sella P, Shostak A: Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum. Perit Dial Bull 5:212-215, 1985
39. Di Paolo N, Sacchi G: Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy. Perit Dial Int 9:41-45, 1989
40. Dobbie JW, Lloyd JK, Gall CA: Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Perit Dial 6:3-12, 1990
41. Honda K, Nitta K, Horita S, Yumura S, Nihei W: Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 72:171-176, 1996
42. Dobbie JW, Anderson JD, Hind C: Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 14 (Suppl 3):S16-S20, 1994
43. Hauglustaine D, Van Meerbeek J, Monballya J, Goddeeris P, Lauwerijns J, Michielsen P: Sclerosing peritonitis with mural fibrosis in a patient on long-term CAPD. Clin Nephrol 22:158-162, 1984
44. Gandhi VC, Humayan HM, Ing TS, Daugirdas JT, Jablokow VR, Iwat Suki S, Geis P, Hano JE: Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 140:1201-1203, 1980
45. Gokal R, Jakubowski C, King J, Hunt L, Bogle S, Baillard R, Marsch F, Ogg C, Oliver D, Ward M, Wilkinson R: Outcome in patients on continuous ambulatory peritoneal dialysis and haemodialysis: 4-year analysis of a prospective multicenter study. Lancet 2:1105-1108, 1987
46. CANUSA Peritoneal Dialysis Study Group: Adequacy of dialysis and nutrition in continuous ambulatory peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol 7:198-207, 1996
47. Genestier J, Hedelin G, Schaffer P, Faller B: Prognostic factors in CAPD patients: A retrospective study of a 10-year period. Nephrol Dial Transplant 10:1905-1911, 1995
48. Shigamatau T: Issues affecting the longevity of the continuous peritoneal dialysis therapy. Kidney Int 52(Suppl 62):S105-S107, 1997
49. Twardowski ZJ: Clinical value of standardized equilibration tests in CAPD patients. Blood Purif 7:95-108, 1989
50. Davies SJ, Brown B, Bryan J, Russel GIL: Clinical evaluation of the peritoneal equilibration test: A population-based study. Nephrol Dial Transplant 8:64-70, 1993
51. Virga G, Amici G, Da Rin G, Vianello A, Calconi G, Da Porto Bocci C: Comparison of fast peritoneal equilibration tests with 1.36% and 3.86% dialysis solutions. Blood Purif 12:113-120, 1994
52. Rippe B: How to measure ultrafiltration failure: 2.27% or 3.86% glucose? Perit Dial Int 17:125-128, 1997.
53. Ho-Dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT: Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 17:144-150, 1997
54. Kush RD, Hallett MD, Ota K, Yamushita A, Kumano K, Watanabe N, Sakai T, Hidai H, Farrell PC: Long-term continuous ambulatory peritoneal dialysis: Mass transfer and nutritional and metabolic stability. Blood Purif 8:1-13, 1990
55. Lameire NH, Vanholder R, Veys D, Lambert MC, Ringoir S: A longitudinal five-year survey of urea kinetic parameters in CAPD patients. Kidney Int 42:426-432, 1992
56. Selgas R, Fernandez-Reyes M-J, Bosque E, Bajo M-A, Borrego F, Jimenez C, Del Peso G, De Alvaro F: Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective median long-term study. Am J Kidney Dis 23:64-73, 1994
57. Davies SJ, Bryan J, Philips L, Russel GI: Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11:448-506, 1996
58. Monquil MCJ, Imholz ALT, Struijk DG, Krediet RT: Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int 15:42-48, 1995
59. Slingeneyer A, Mion C, Mourad G, Canaud B, Faller B, Béraud JJ: Progressive sclerosing peritonitis: A late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Intern Organs 29:633-640, 1983
60. Krediet RT, Struijk DG, Boeschoten EW, Koomen GCM, Stouthard JML, Hoek FJ, Arisz L: The time course of peritoneal transport kinetics in continuous ambulatory peritoneal dialysis patients who develop sclerosing peritonitis. Am J Kidney Dis 13:299-307, 1989
61. Hendriks PMEM, Ho-Dac-Pannekeet MM, Van Gulik THM, Struijk DG, Phoa SSKS, Sie LH, Kox C, Krediet RT: Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors and peritoneal transport kinetics. Perit Dial Int 17:136-143, 1997
62. Dobbie JW, Krediet RT, Twardowski ZJ, Nichols WK: A 39-year old man with loss of ultrafiltration. Perit Dial Int 14:384-394, 1994
63. Ho-Dac-Pannekeet MM, Koopmans JG, Struijk DG, Krediet RT: Restriction coefficients of low molecular weight solutes and macromolecules during peritoneal dialysis. Adv Perit Dial 13:72-76, 1997
64. Struijk DG, Krediet RT, Koomen GCM, Boeschoten EW, Hoek FJ, Arisz L: A prospective study of peritoneal transport in CAPD patients. Kidney Int 45:1739-1744, 1994
65. Struijk DG, Krediet RT, Koomen GCM, Hoek FJ, Boeschoten EW, Van Der Reijden HJ, Arisz L: Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis. Nephron 59:213-220, 1991
66. Ziegler C, Torchia M, Grahame GR, Ferguson IA: Peritoneal surface-active material in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 9:47-49, 1989
67. Krack G, Viglino G, Cavelli PL, Gandolfo C, Magliano G, Cantaluppi A, Peluso F: Intraperitoneal administration of phosphatidylcholine improves ultrafiltration in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 12:359-364, 1992
68. Ho-Dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT: Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial 13:17-22, 1997
69. Ho-Dac-Pannekeet MM: Peritoneal fluid markers of mesothelial cells and function. Adv Renal Replace Ther 5:205-211, 1998
70. Topley N, Liberek T, Davenport A, Li FK, Fear H, Williams JD: Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Kidney Int 50(Suppl 56):S17-S21, 1996
71. Visser CE, Brouwer-Steenbergen JJE, Schadee-Eestermans IL, Meijer S, Krediet RT, Beelen RHJ: Ingestion of Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli by human peritoneal mesothelial cells. Infect Iinmunol 64:3425-3428, 1996
72. Betjes MGH, Bos HJ, Krediet RT, Arisz L: The mesothelial cells in CAPD effluent and their correlation to peritonitis incidence. Perit Dial Int 11:22-26, 1991
73. Koopmans JG, Boeschoten EW, Pannekeet MM, Betjes MGH, Zemel D, Kuiper EJ, Krediet RT: Impaired initial cell reaction in CAPD-relaled peritonitis. Perit Dial Int 16(Suppl 1):S362-S367, 1996
74. Rottembourg J, Gahl GM, Poignet JL, Mertani E, Strippoli P, Langlois P, Tranbaloc P, Legrain M: Severe abdominal complications in patients undergoing continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 20:236-242, 1983
75. Junor BJR, Briggs JD, Forwell MA, Dobbie JW, Henderson I: Sclerosing peritonitis - the contribution of chlorhexidine in alcohol. Perit Dial Bull 5:101-104, 1985
76. Slingeneyer A: Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. Contrib Nephrol 57:239-247, 1987
77. Oulès R, Challah S, Brunner FP: Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 3:66-69, 1988
78. Campbell S, Clarke P, Hawley C, Wigan M, Kerlin P, Butler J, Wall D: Sclerosing peritonitis: Identification of diagnostic, clinical and radiological features. Am J Kidney Dis 24:819-825, 1994
79. Nilsson-Thorell CB, Muscalu N, Audrér AHG, Kjellstrand PTT, Wieslander AP: Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 13:208-213, 1993
80. Breborowicz A, Rodella H, Oreopoulos DG: Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 41:1280-1285, 1992
81. Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD: Effect of lactate buffered peritoneal dialysis fluid on human peritoneal mesothelial cells, interleukin-6 and prostaglandin synthesis. Kidney Int 46:282-293, 1994
82. Pedersen FB, Ryttov N, Deleuran P, Dragsholt C, Kildeberg P: Acetate versus lactate in peritoneal dialysis solution. Nephron 39:55-58, 1985
83. Gotloib L, Waisbrut V, Shostak A, Kushnier R: Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose enriched, laclated, buffered dialysis solutions. Nephron 70:466-477, 1995
84. Gotloib L, Shostak A, Waysbrot V: Detrimental effects of peritoneal dialysis solutions upon in vivo and in situ exposed mesothelium. Perit Dial Int 17(Suppl 2):S13-S16, 1997
85. Lamb E, Catell WR, Dawnay A: Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis. Clin Sci 84:619-626, 1993
86. Davin JC, Bouts AHM, Krediet RT, Van Der Weel M, Weening RS, Groothoff J, Out TA: IgG glycation and function during continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 12:310-314, 1997
87. Yamada K, Miyakasa Y, Hamaguchi K, Nakayama M, Nakano H, Nozaki O, Miura Y, Suzuki S, Tuchida H, Mimura N, Araki N, Horiuchi S: Immunohistochemical study of human advanced glycosylation end products (AGE) in chronic renal failure. Clin Nephrol 42:354-361, 1994
88. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katok N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 51:182-186, 1997
89. Rigby RJ, Hawley SM: Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant 13:154-159, 1998
90. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K: Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of the Japanese sclerosing encapsulating peritonitis study group. Am J Kidney Dis 28:420-427, 1996
91. Miranda B, Selgas R, Celadilla O, Muñoz J, Sánchez Sicilia L: Peritoneal resting and heparinization as an effective treatment for ultrafiltration failure in patients on CAPD. Contrib Nephrol 89:199-204, 1991
92. Da Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez-Reyes MJ, Romero JR, Jimenez C, Miranda B, Selgas R: Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 9:56-61, 1993
93. Burkhart J, Stallard R: Result of peritoneal membrane (PM) resting (R) on dialysate (d) CA125 levels and PET results (abstract). Perit Dial Int 17(Suppl 1):S5, 1997
94. Simonsen O, Wieslander A, Landgren C, Rippe B: Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid. Adv Perit Dial 12:156-160, 1996
95. Matthys E, Dolkart R, Lameire N: Extended use of a glycerol-containing dialysate in diabetic CAPD patients. Perit Dial Bull 7:10-15, 1987
96. Mistry CD, Gokal R, Peers E, MIDAS Study Group: A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 46:496-503, 1964
97. Stein A, Peers E, Hattersley J, Harris K, Feehally J, Walls J, MIDAS Study Group: Clinical experience with icodextrin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 14(Suppl 2):S51-S54, 1994
98. Imholz ALT, Brown CB, Koomen GCM, Arisz L, Krediet RT: The effect of glucose polymers on water removal and protein clearances during CAPD. Adv Perit Dial 9:25-30, 1993
99. Ho-Dac-Pannekeet MM, Struijk DG, Krediet RT: Improvement of transcellular water transport by treatment with glucose free dialysate in patients with ultrafiltration failure (abstract). Nephrol Dial Transplant 11:A255, 1996
100. Pannekeet MM, Imholz ALT, Struijk DG, Koomen GCM, Langedijk MJ, Schouten N, De Waart R, Hirallal J, Krediet RT: The standard peritoneal permeability analysis: A tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 48:866-875, 1995
101. Singh S, Wadhwa N: Peritonitis, pancreatitis, and infected pseudocyst in a continuous ambulatory peritoneal dialysis patient. Am J Kidney Dis 9:84-86, 1987
102. Pannekeet MM, Krediet RT, Boeschoten EW, Arisz L: Acute pancreatitis during CAPD in the Netherlands. Nephrol Dial Transplant 8:1376-1381, 1993
103. Gupta A, Yuan ZY, Balaskas EV, Khanna R, Oreopoulos DG: CAPD and pancreatitis: No connection. Perit Dial Int 12:309-316, 1992
104. Valderrbano F, Jones EHP, Mallick NP: Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 10(Suppl. 5):1-25, 1995
105. Held PJ, Port FK, Turenne MN, Gaylin DS, Hamburger RJ, Wolfe RA: Continuous ambulatory peritoneal dialysis and hemodialysis: Comparison of patient mortality with adjustment for comorbid conditions. Kidney Int 45:1163-1169, 1994
106. Viglino G, Cancarini GC, Catizone L, Cocchi R, De Vecchi A, Lupo A, Salomone M, Segoloni GP, Giangrande A: Ten years experience of CAPD in diabetics: Comparison of results with non-diabetics. Nephrol Dial Transplant 1994:1443-1448, 1994
107. Nolph DK, Staltz ML, Maher JF: Altered peritoneal permeability in patients with systemic vasculitis. Ann Intern Med 75:753-755, 1971
108. Rubin J, Nolph KD, Arfania D, Brown P, Moore H, Rust P: Influence of patient characteristics on peritoneal clearances. Nephron 27:118-121, 1981
109. Rubin J, Walsh D, Bower JD: Diabetes, dialysate losses and serum lipids during continuous ambulatory peritoneal dialysis. Am J Kidney Dis 10:104-108, 1987
110. Selgas R, Madero R, Muñoz J, Huarte E, Riñon C, Miguel JL, Sanchez-Sicilia L: Functional peculiarities of the peritoneum in diabetes mellitus. Dial Transplant 17:419-436, 1988
111. Lin JJ, Wadhwa NK, Suh H, Cabralda T, Patlak CS: Increased peritoneal solute transport in diabetic peritoneal dialysis patients. Adv Perit Dial 11:63-66, 1995
112. Lamb EJ, Worrall J, Buhler R, Harwood S, Cattell WR, Dawnay AB: Effect of diabetes and peritonitis on the peritoneal equilibration test. Kidney Int 47:1760-1767, 1995
113. Serlie MJM, Struijk DG, De Blok D, Krediet RT: Differences in fluid and solute transport between diabetic and nondiabetic patients at the onset of CAPD. Adv Perit Dial 13:29-32, 1997
114. De Fijter CW, Oe LP, Nauta JJ, Van Der Meulen J, Verbrugh HA, Verhoef J, Donker AJM: Clinical efficacy and morbidity associated with continuous cyclic compared with continuous ambulatory peritoneal dialysis. Ann Intern Med 120:264-271, 1994
115. Lameire N, Van Biesen W, Van Landsaat M, Wang T, Heimbürger O, Bergström J, Lindholm B, Hekking LPH, Havenith CEG, Beelen RHJ: Animal models in peritoneal dialysis: A European experience. Kidney Int (in press)
116. Schambye HT, Pedersen RB, Flesner P, Hardt-Madsen M, Antonsen S, Chemnitz J, Pedersen FB, Detmer A: Experimental model for CAPD studies in the rabbit. Scand J Lab Animal Sci 19:113-123, 1992
117. Schambye HT, Flesner P, Pedersen RB, Hardt-Madsen M, Chemnitz J, Christensen HK, Detmer A, Pedersen FB: Bicarbonate-versus lactate-based CAPD fluids: A biocompatibility study in rabbits. Perit Dial Int 12:281-286, 1992
118. Zweers MM, Douma CE, De Waart DR, Van Der Waardt AB, Ho-Dac-Pannekeet MM, Krediet RT, Struijk DG: The standard peritoneal permeability analysis in the rat; a longitudinal model for peritoneal dialysis. Perit Dial Int (in press)
119. Hekking LHP, Aalders MC, Van Gelderop E, Zweers MM, Struijk DG, Havenith CEG, Beelen RHJ: Effect of peritoneal dialysis fluid measured in an in vivo model for continuous peritoneal dialysis in the rat. Adv Perit Dial 14:14-18, 1998
120. Gokal R, Mistry CD, Peers E, MIDAS Study Group: Peritonitis occurrence in a multicenler study of icodextrin and glucose in CAPD. Perit Dial Int 15:226-230, 1995
121. Douma CE, Hiralall JK, De Waart DR, Struijk DG, Krediet RT: Icodextrin with nitroprusside increases ultrafiltration and peritoneal transport during long CAPD dwells. Kidney Int 53:1014-1021, 1998
122. Davies SJ, Phillips L, Russell GI: Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 13:962-968, 1998
123. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Pagé D, CANUSA Study Group: Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 9:1285-1292, 1998
124. Coles GA: Have we underestimated the importance of fluid balance for the survival of PD patients? Perit Dial Int 17:321-326, 1997
125. Jensen T: Increased plasma concentration of von Willebrand factor in insulin dependent diabetics with incipient nephropathy. BMJ 298:27-28, 1989
126. Knepper MA:The aquaporin family of molecular water channels. Proc Natl Acad Sci USA 91:6255-6258, 1994
127. Carlsson O, Nielsen S, Zakaria ER, Rippe B: In vivo inhibition of transcellular water channels (aquaporin-1 ) during acute peritoneal dialysis in rats. Am J Physiol 271 (Heart Circ Physiol 40):H2254-H2262, 1996
128. Jörres A, Ludat K, Sander K, Dunkel K, Lorenz F, Keck H, Frei U, Gahl GM: The peritoneal fibroblast and the control of peritoneal inflammation. Kidney Int 50(Suppl 56):S22-S27, 1996
129. Zemel D, Koomen GCM, Hart AAM, Ten Berge RJM, Struijk DG, Krediet RT: Relationship of TNF β, interleukin-6 and prostaglandins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 122:686-696, 1993
130. Ripley EBD, Gehr TWB, Kish CW, Sica DA: Hormonal, blood pressure, and peritoneal transport response to short-term ACE inhibition. Perit Dial Int 14:378-383, 1994
131. Favazza A, Montanero D, Messa P, Antonucci F, Gropuzzo M, Mioni G: Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril and nifedipine. Perit Dial Int 12:287-291, 1992
132. Myrup B, Hansen PM, Jensen T, Kofold-Enevaldsen A, Feldt-Rasmussen B, Gram J, Kluft C, Jespersen J, Deckert T: Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345:421-422, 1995
133. Tamsma JT, Van Der Woude FJ, Lemkes HHPJ: Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol Dial Transplant 11:182-185, 1996
134. Wolthuis A, Boes A, Berden JHM, Grond J: Heparins modulate extracellular matrix and protein synthesis of cultured rat mesangial cells. Virchows Arch B, Cell Pathol 63:181-189, 1993
135. Bazzato G, Fracasso A, Gambaro G, Baggio B: Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet 346:740-741, 1995
136. Gambaro G, Cavazzano AO, Luzi P, Piccoli A, Borsatti A, Crepaldi G, Marchi E, Venturini P, Baggio B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 42:285-291, 1992
137. Gotloib L, Bar-Sella P, Jaichenko J, Shusta A: Rutheniumred-stained polyanionic fixed changes in peritoneal microvessels. Nephron 47:22-28, 1987
138. Gotloib L, Shustak A, Jaichenko J: Loss of mesothelial electro-negative fixed charges during murine septic peritonitis. Nephron 51:77-83, 1989
139. Krediet RT, Koomen GCM, Koopman MG, Hoek FJ, Struijk DG, Boeschoten EW, Arisz L: The peritoneal transport of serum proteins and neutral dextran in CAPD patients. Kidney Int 35:1064-1072, 1989
140. Krediet RT, Struijk DG, Koomen GCM, Zemel D, Boeschoten EW, Hoek FJ, Arisz L: Peritoneal transport of macromolecules in patients on CAPD. Contrib Nephrol 89:161-174, 1991
141. Buis B, Koomen GCM, Imholz ALT Struijk DG, Reddingius RE, Arisz L, Krediet RT: Effect of electric charge on the transperitoneal transport of plasma proteins during CAPD. Nephrol Dial Transplant 11:1113-1120, 1996
142. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofold-Evevaldsen A: Albuminuria reflects widespread vascular damage: The Steno hypothesis. Diabetologia 32:219-226, 1989
143. Van Den Born J, Van Den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assmann KJM, Berden JHM: A monoclonal antibody againsl GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41:115-123, 1992
144. Agre P, Preston GM, Smith BL, Jung SJS, Raina S, Moon C, Guggiono WB, Nielsen S: Aquaporin CHIP: The archetypal molecular water channel. Am J Physiol 265(Renal Fluid Electrolyte Physiol 34):F463-F476, 1993
145. Bowers VD, Ackermann JR, Richardson W, Carey LC: Sclerosing peritonitis. Clin Transplant 8:369-372, 1994
146. Bhandari S, Wilkinson A, Sellars L: Sclerosing peritonitis: Value of immunosuppression prior to surgery. Nephrol Dial Transplant 9:436-437, 1994
147. Junor BJR, MCMillan MA: Immunosuppression in sclerosing peritonitis. Adv Perit Dial 9:187-189, 1993
148. Krediet RT, Zuyderhoudt FMJ, Boeschoten EW, Arisz L: Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 17:43-52, 1987
149. Verger C, Cilicout B: Peritoneal permeability and encapsulating peritonitis. Lancet 1:986-987, 1985
150. Hagmolen of Ten Have W, Ho-Dac-Pannekeet MM, Struijk DG, Krediet RT: Mesothelial regeneration after peritonitis in dialysis patients (abstract). J Am Soc Nephrol 8:180A, 1997
151. Campbell S, Clarke P, Hawley C, Wigan M, Kerlin P, Butler J, Wall D: Sclerosing peritonitis: Identification of diagnostic, clinical and radiologic features. Am J Kidney Dis 24:814-825, 1994
152. Nagy JA: Peritoneal membrane morphology and function. Kidney Int 50(Suppl 56):S2-S11, 1996